Loading...

OCX ONCOCYTE CORP Disposals and divestitures 8-K Filing

NCCY

CX

ONCOCYTE CORP

(OCX)

2023 8-K

Show Summary

Show Summary

Financial Statements

Accountant Change

Financial Results

Executive Changes

Lease Amendment

Financial Results

Equity Incentive Plan

Private Placement

Sales Agreement

Financial Results Announcement

Meeting Results

Appointment of CFO

Salary Increases

Management Agreement

Earnings Reports

Securities Purchase Agreement

Collaboration Agreement

Earnings Reports

Accountant Engagement

Change of Auditor

Sublease Agreement

Financial Results and Manag...

Annual Meeting of Shareholders

Appointment of CEO

Financial Results and CFO D...

Reduction in Force

Registered Direct Offering

Financial Results

Financial Results Announcement

Appointment of CEO

Sale of Subsidiary

Merger Agreement and Termin...

Stock Purchase Agreement Am...

External Links:

Oncocyte Corp completed the sale of 70% of its subsidiary Razor Genomics, eliminating development and commercialization costs for DetermaRxTM test.

AI Assistant

ONCOCYTE CORP

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.